Core Scientific's stock has exhibited a strong recovery over the past year, with a 1-year price change of +53.03%, significantly outperforming the S&P 500's +18.19% over the same period. The current price of $20.72 sits at approximately 68% of the 52-week range (between $12.595 low and $30.46 high), indicating the stock is in the upper half of its range but has pulled back from its highs. This positioning suggests a healthy consolidation after a strong uptrend, rather than an overextended or broken chart, though the recent decline from the June peak warrants attention. The stock's beta of 5.495 indicates extreme volatility, roughly 5.5 times the market's, which is a critical consideration for risk management.

Revenue has shown strong growth, with the most recent quarter (Q1 2026) reporting revenue of $115.244 million, up 44.92% year-over-year, and the company has seen sequential growth from $79.763 million in Q4 2025. This growth is driven by the Digital Asset Mining Service segment, which contributed $149.959 million in revenue, and Hosting Service at $20.081 million, though the company's overall revenue is still modest relative to its market cap. However, the company remains unprofitable, with a net loss of -$347.188 million in Q1 2026, and a net margin of -90.47% on a trailing basis, though gross margin improved to 25.81% in Q1 2026 from 26.18% in Q4 2025, indicating some operational leverage. The balance sheet shows a debt-to-equity ratio of -1.10, which is negative due to negative shareholders' equity, and a current ratio of 1.15, indicating adequate short-term liquidity, but the company's free cash flow is deeply negative at -$471.202 million TTM, reflecting heavy capital expenditures for infrastructure expansion.